On March 18, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported that it will present four posters at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 17–22 at the San Diego Convention Center in San Diego, California. The presentations will include one poster featuring data from BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612), two posters highlighting further analyses of Phase 2 data, and one poster presenting preclinical data related to Bria-OTS+, BriaCell’s next-generation personalized off-the-shelf immunotherapy for cancer. Abstracts will be published in the online Proceedings of the AACR (Free AACR Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With four posters presenting positive clinical and preclinical data, we are expanding the body of evidence supporting the efficacy and favorable safety profile of our novel immunotherapy, with the goal of improving care for patients with cancer who remain in urgent need of new treatment options," stated William V. Williams, MD, BriaCell’s President & CEO.

Session Title: Phase II and Phase III Clinical Trials
Session: 4/20/2026 2:00-5:00 PM
Location: Poster Section 52
Poster Board Number: 1
Poster Number: CT137
Title: QOL Outcomes in Bria-ABC Late-Stage Metastatic Phase 3 Trial
Summary: Heavily pretreated metastatic breast cancer patients in the pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor maintained overall health status and key functional measures with a favorable safety profile. These findings are encouraging because they suggest meaningful preservation of quality of life for late-stage metastatic breast cancer patients with limited treatment options.

Session Category: Clinical Research
Session Title: Vaccines and Other Immunomodulatory Agents
Session: 4/21/2026 2:00-5:00 PM
Location: Poster Section 49
Poster Board Number: 12
Poster Number: 6701
Title: Re-Engineering Cancer Vaccines: Bria-OTS+ Integrates Innate and Adaptive Immunity for Broad and Persistent Anti-Tumor Responses
Summary: Bria-OTS+ is a personalized off-the-shelf next-generation, genetically engineered whole-cell cancer immunotherapy platform designed for better efficacy and safety. Our findings indicated that Bria-OTS+ immunotherapy targeting breast, prostate, lung and melanoma activated key components of both the innate and adaptive immune system to broadly attack and destroy cancer cells. These include coordinated activation of CD4⁺/CD8⁺ T, NK, NKT and B cells, increased cytokine release and persistent immune competence without exhaustion – combating a known cause of cancer progression.

Session Category: Clinical Research
Session: 4/19/2026 2:00-5:00 PM
Location: Poster Section 42
Poster Board Number: 5
Poster Number: 1065
Title: Mitosis in Circulating Tumor Cells Correlates with Highly Aggressive Disease in Metastatic Breast Cancer

Session Category: Clinical Research
Session Title: Biomarkers Predictive of Therapeutic Benefit 1
Session: 4/19/2026 2:00-5:00 PM
Location: Poster Section 40
Poster Board Number: 19
Poster Number: 1025
Title: Monitoring PD-L1 in tumor macrophage fusion cells in blood identifies high PD-L1 checkpoint inhibitor responses in metastatic breast cancer

Following the presentation, copies of the posters will be made available at View Source

(Press release, BriaCell Therapeutics, MAR 18, 2026, View Source [SID1234663732])

On March 18, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, reported that updated pre-clinical data for MDNA113, its first-in-class PD-1 x IL-2 bifunctional superkine advancing toward an IND submission in H2 2026, will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17–22 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentation are as follows:

Title: MDNA113 is a masked conditionally activated tumor-targeted anti-PD1-IL-2SK with superior safety and therapeutic properties.
Session Title: Monoclonal Antibodies and Antibody-Cytokine Platforms
Session Date and Time: Tuesday, April 21st, 2026; 9:00 AM – 12:00 PM
Location: Poster Section 9
Poster Board Number: 13
Abstract Number: 4342

Following the presentation, a copy will be available on the "Scientific Presentations" page of Medicenna’s website.

About MDNA113:

MDNA113 is a novel, first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL-2 Superkine with exceptionally high affinity for IL-13Rα2 without binding to the functional IL-13R⍺1. IL-13Rα2 is overexpressed in a wide range of solid tumors, including cold tumors with minimal to no expression in normal tissues. IL-13Rα2 expressing tumors also have abundant matrix metalloprotease in the tumor microenvironment that may efficiently activate MDNA113. IL-13Rα2 expression is associated with poor clinical outcome in multiple tumor types including prostate, pancreatic, ovarian, liver, breast and brain cancer, with an annual world-wide incidence of over 2 million.

(Press release, Medicenna Therapeutics, MAR 18, 2026, View Source [SID1234663731])

On March 18, 2026 Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, reported that the company’s partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziihera (zanidatamab-hrii) at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 17-22, 2026 in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to see the continued clinical progress of zanidatamab reflected in multiple presentations at AACR (Free AACR Whitepaper)," said Ken Galbraith, Chair, Chief Executive Officer, and Interim Chief Financial Officer of Zymeworks. "These studies highlight emerging data evaluating zanidatamab across tumor types beyond biliary tract cancer and gastroesophageal adenocarcinoma, and contribute to the growing body of evidence supporting its potential across HER2-expressing cancers."

Highlights at the AACR (Free AACR Whitepaper) Annual Meeting include:

An oral presentation with results from the Phase 2 single-arm, open-label NeoZanHER trial (NCT05035836) evaluating zanidatamab for the investigational use as neoadjuvant monotherapy in patients with early-stage HER2+ breast cancer. At six weeks, zanidatamab treatment resulted in a statistically significant decrease in tumor size and volume from baseline, and 30% of patients (n=6) achieved pathologic complete response (pCR). Treatment with zanidatamab was manageable with no new safety signals.
A poster presentation detailing mechanistic and multi-omics analyses characterizing zanidatamab’s differentiated HER2 biology, including dual, domain-specific binding and downstream effects on key cellular signaling pathways, with insights into activity in models following progression on trastuzumab deruxtecan (T-DXd).
Additional presentations further explore zanidatamab’s utility across HER2-expressing solid tumors and within innovative biomarker-driven clinical trial designs, including adaptive organ-preservation strategies in gastroesophageal adenocarcinoma.

Oral Presentation

Title: A Phase 2 Single-Arm Open-Label Trial Evaluating Zanidatamab in Patients with Early Stage HER2 positive Breast Cancer: The NeoZanHER Study
Presentation Number: CT012
Session: Clinical Trials Minisymposium: Aiming for Cure: Perioperative Clinical Trials
Date/Time: Saturday, April 18, 2026 at 12:30 – 2:30 pm Pacific Standard Time (PST)

Poster Presentations

Title: Zanidatamab Modulates Multiple Pathways Involved in Tumor Growth and Survival is Efficacious Post-T-DXd
Abstract: 452
Session: Experimental and Molecular Therapeutics: Next-Generation Targeted Therapies Directed Against Tumor Surface Antigens
Date/Time: Tuesday, April 21, 2026 at 9:00 am – 12:00 pm PST

Title: DiscovHER PAN-206: Phase 2 Tumor-Agnostic Study of Zanidatamab in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Overexpressing Solid Tumors
Abstract: CT209
Session: Phase II and Phase III Clinical Trials in Progress
Date/Time: Tuesday, April 21, 2026 at 9:00 am – 12:00 pm PST

Title: AACR (Free AACR Whitepaper) Adaptive Biomarker-Driven Organ Preservation Trial in GE Adenocarcinomas (AACR-ADOPT-GEA)
Abstract: CT223
Session: Phase II and Phase III Clinical Trials in Progress
Date/Time: Tuesday, April 21, 2026 at 9:00 am – 12:00 pm PST

The AACR (Free AACR Whitepaper) abstracts are available at View Source!/21436.

About Ziihera (zanidatamab-hrii)

Ziihera (zanidatamab-hrii) is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab-hrii with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab-hrii induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo. In the United States, Ziihera is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.1 The FDA granted accelerated approval for this indication based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).1

Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is being developed by Jazz and BeOne under license agreements from Zymeworks, which first developed the molecule.

The FDA granted two Breakthrough Therapy designations for zanidatamab’s development: one as a single agent for previously treated HER2 gene-amplified BTC, and one in combination with standard-of-care chemotherapy for first-line HER2+ locally advanced or metastatic GEA. The FDA also granted two Fast Track designations for zanidatamab: one as a single agent for refractory BTC and one in combination with standard-of-care chemotherapy for first-line GEA. Additionally, zanidatamab has received Orphan Drug designations from the FDA for the treatment of BTC, gastric (including gastroesophageal junction) cancer, and esophageal cancer, as well as Orphan Drug designations from the European Medicines Agency for the treatment of BTC, gastric/gastroesophageal junction cancer and oesophageal cancer.

The full U.S. Prescribing Information for Ziihera, including BOXED Warning, is available at: View Source

(Press release, Zymeworks, MAR 18, 2026, View Source [SID1234663730])

On March 18, 2026 Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, reported the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in San Diego, California from April 17-22, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract was selected for oral presentation as part of the Clinical Trials Mini Symposium.

Oral Presentation

Title: First-in-human phase I study of PLN-101095, a first-in-class dual αvβ8/αvβ1integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)

Presenter: Timothy A. Yap, M.D., Ph.D., University of Texas, M.D. Anderson Cancer Center
Session: CTMS01: Updates in Anticancer Immunotherapies
Date: Saturday, April 18, 2026
Presentation Time: 10:21 a.m. – 10:31 a.m. Pacific Time
Location: Ballroom 6A – Upper Level – San Diego Convention Center

Oncology Program

PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins designed to overcome checkpoint resistance by blocking TGF-β activation in the tumor microenvironment. Pliant is currently conducting a Phase 1a/1b open-label, dose-escalation and indication expansion trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095, as monotherapy and in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors.

(Press release, Pliant Therapeutics, MAR 18, 2026, View Source [SID1234663729])

On March 18, 2026 Totus Medicines, a clinical stage, precision medicine company leveraging a novel covalent DNA-encoded library + AI-powered small molecule drug discovery platform to advance a differentiated pipeline of therapeutics against high-value, historically difficult to drug targets in multiple therapeutic areas, reported the presentation by Dr. Antonio Giordano of Dana Farber Cancer Center of new clinical data for TOS-358, its lead oral covalent PI3Ka inhibitor, in an oral presentation at the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Congress in Paris, France.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"TOS-358 was designed to overcome the limitations of currently available PI3Ka inhibitors by delivering sustained and specific, >90% covalent inhibition of the target combined with a best-in-class safety profile," said Zelanna Goldberg, M.D., Chief Medical Officer of Totus Medicines. "We are very encouraged by the early clinical efficacy data, which demonstrate durable tumor control and class-leading tolerability in heavily pretreated patients, including those who had previously progressed on other PI3K pathway therapies.

"TOS-358 is amongst the most interesting agents in this class to emerge. It appears to be a well-tolerated and straightforward drug to give for PI3Ka mutant disease with early data suggesting the potential for meaningfully durable tumor control. This may help inhibit tumor growth and maintain quality of life, which is a promising combination for our patients" said Dr. Antonio Giordano.

TOS-358 is an oral, highly selective, pan-mutant, covalent PI3Ka inhibitor that achieves >95% continuous target engagement for deep and durable inhibition of PI3K-AKT signaling which is required for optimal efficacy and durability.

Phase 1a Key Clinical Findings:

Clinical results from the efficacy cohort demonstrated encouraging anti-tumor activity and durability of response:

Overall efficacy profile:

CBR: 50%
DCR: 75%
ORR: 15%
≥20% tumor shrinkage: 40%
Patients on therapy for ≥24 weeks: 45%

Clinically meaningful disease control in heavily pre-treated patients:

DCR in PAM-resistant patients: 67%
DCR in PAM-intolerant patients: 100%

Class-leading Safety & Tolerability Profile:

TOS-358 demonstrated a favorable and differentiated safety profile, with minimal gastrointestinal or epithelial toxicities.

Key observations included:

No bone marrow toxicity
No hepatic toxicity
No renal toxicity
No ocular symptoms
No rash
No stomatitis or mucositis
<5% of patients required medication for nausea or diarrhea

Hyperglycemia, an expected on-target effect of PI3Ka inhibition, was primarily low grade and manageable with oral medications. Only 3.6% (2/54 pts) required ongoing insulin, which is similar to, or lower than, other PI3Ka inhibitors in development including mutant selective and/or allosteric compounds.

Phase 1b study design:

TOS-358 is currently being evaluated in an ongoing Ph1b study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of TOS-358 in combination with fulvestrant and in combination with fulvestrant and CDK inhibitors in patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer. Initial data from these combination cohorts are expected to be presented at future medical and scientific conferences.

(Press release, Totus Medicines, MAR 18, 2026, View Source [SID1234663728])